Goldman Sachs Group, Inc. (The) restated their neutral rating on shares of Radius Health, Inc. (NASDAQ:RDUS) in a report released on Friday morning, MarketBeat.com reports. The firm currently has a $45.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity set a $85.00 target price on shares of Radius Health and gave the stock a buy rating in a research report on Monday, July 31st. Cantor Fitzgerald set a $58.00 target price on shares of Radius Health and gave the stock a buy rating in a research report on Sunday, July 23rd. BidaskClub raised shares of Radius Health from a hold rating to a buy rating in a research report on Tuesday, June 27th. Jefferies Group LLC reissued a hold rating and set a $38.00 target price (up from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Finally, Zacks Investment Research raised shares of Radius Health from a sell rating to a hold rating in a research report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. Radius Health currently has an average rating of Hold and a consensus price target of $52.17.

Radius Health (NASDAQ:RDUS) opened at 38.76 on Friday. Radius Health has a 1-year low of $31.58 and a 1-year high of $55.97. The stock’s 50 day moving average is $36.59 and its 200-day moving average is $38.70. The firm’s market capitalization is $1.69 billion.

Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.23). The firm had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.96 million. During the same period in the previous year, the firm posted ($1.01) earnings per share. Analysts forecast that Radius Health will post ($5.58) EPS for the current year.

WARNING: “Radius Health, Inc. (RDUS) Earns Neutral Rating from Goldman Sachs Group, Inc. (The)” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/10/09/radius-health-inc-rdus-earns-neutral-rating-from-goldman-sachs-group-inc-the.html.

In other news, insider Jesper Hoiland purchased 6,100 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The shares were acquired at an average cost of $32.72 per share, for a total transaction of $199,592.00. Following the completion of the acquisition, the insider now owns 6,100 shares in the company, valued at $199,592. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jose Carmona purchased 3,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were purchased at an average price of $32.83 per share, for a total transaction of $98,490.00. Following the completion of the acquisition, the chief financial officer now owns 3,000 shares of the company’s stock, valued at approximately $98,490. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 469,100 shares of company stock worth $16,328,382. 15.00% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. BB Biotech AG boosted its holdings in Radius Health by 11.0% during the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock worth $227,905,000 after purchasing an additional 498,400 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in Radius Health by 18.3% during the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock worth $166,731,000 after purchasing an additional 569,300 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Radius Health by 4.5% during the second quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock worth $142,281,000 after purchasing an additional 135,071 shares during the last quarter. BlackRock Inc. boosted its holdings in Radius Health by 10.0% during the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock worth $130,881,000 after purchasing an additional 262,896 shares during the last quarter. Finally, State Street Corp boosted its holdings in Radius Health by 12.9% during the second quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after purchasing an additional 213,399 shares during the last quarter.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.